Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind placebo-controlled phase 2 dose-finding study of namilumab plus methotrexate in moderate to severe rheumatoid arthritis
jRCT2080222927Phase 2
- Sponsor
- Takeda
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of namilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Takeda.
02
Drugs
namilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222927.